Jump to Navigation

Facebook Connect

User login

2011 NLA Scientific Sessions Highlights

Philip J. Barter, MD, PhD

Clinical Trial Updates Impacting Your Practice

Faculty: Philip J. Barter, MD, PhD

Tags:

Prof. Barter reviews some recent trials with fibrates, statins, and niacin that he believes should have an impact on current clinical practice.

play
Summary
pdf
MP3 Audio
0
No votes yet
Jonathan C. Cohen, PhD

What Do Simple Genetics Tell Us About Complex Diseases?

Faculty: Jonathan C. Cohen, PhD

Tags:

In the Keynote Presentation of the 7th Annual Scientific Sessions, Dr Cohen reviewed what "simple" genetics can tell us about coronary heart disease (CHD).

play
Summary
pdf
MP3 Audio
0
No votes yet
JoAnne M. Foody, MD, FACC, FAHA

The Impact of Prescription Switching on LDL-C Goal Attainment

Faculty: JoAnne M. Foody, MD, FACC, FAHA

Tags:

Dr Foody focused on the unintended consequences of formulary changes and the potentially harmful effects, with respect to providing evidence-based care or meeting therapeutic goals. She noted that in the United Kingdom (UK), forced switching of high-dose to low-dose statin resulted in higher rates of death, cardiac death, and non-cardiac death in individuals switched to the lower dose.

play
Summary
pdf
MP3 Audio
0
No votes yet
Henry N. Ginsberg, MD

Common Etiologies of Hypertriglyceridemia

Faculty: Henry N. Ginsberg, MD

Tags:

At least 95% of people with type-2 diabetes are insulin resistant. In the adipose tissue, insulin-resistant cells release fatty acids, increasing fatty acid flux to the liver resulting in transformation of the excess into triglycerides (TG)

play
Summary
pdf
MP3 Audio
0
No votes yet
Georgirene D. Vladutiu, PhD

Genetic Susceptibility to Statin-Induced Myopathy

Faculty: Georgirene D. Vladutiu, PhD

Tags:

Severe statin myopathy is usually defined as severe muscle damage with damage to another organ, such as a kidney, and creatinine kinase (CK) ≥10 x upper limit of normal (ULN). However, some severely affected patients have serum CK <10 x ULN. Of 166 patients with severe statin myopathy referred to Dr Vladutiu's laboratory, 40% had CK ≥10 x ULN, 30% had CK 4-9 x ULN, and 10-15% had CK 2-3 x ULN.

play
Summary
pdf
MP3 Audio
0
No votes yet
M. John Chapman, PhD, DSc, FESC

Novel Therapies on the Horizon

Faculty: M. John Chapman, PhD, DSc, FESC

Tags:

According to Dr. Chapman, there are a number of therapeutic agents on the horizon that normalize levels of Apolipoprotein A-I (ApoA-I) and high-density lipoprotein cholesterol (HDL-C) for the acute and/or chronic treatment of patients at high cardiometabolic risk.

play
Summary
pdf
MP3 Audio
4
Average: 4 (1 vote)
Eric C. Westman, MD, MHS

The Case For A Low-Fat/Good Carbohydrate Diet

Faculty: Eric C. Westman, MD, MHS

Tags:

In his presentation, Dr Westman sought to dispel some "myths" and answer criticisms about the low-carbohydrate (low-carb) diet. He maintains that someone in a wheelchair can lose weight, even if they do not exercise, just by changing their diet.

play
Summary
pdf
MP3 Audio
0
No votes yet
John P. Foreyt, PhD

The Case For A Low-Fat/Good Carbohydrate Diet

Faculty: John P. Foreyt, PhD

Tags:

All major dietary guidelines, including those of the Institute of Medicine (IOM), the American Dietetic Association (ADA), and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), all recommend 25-30% calories come from fat, i.e., a low-fat diet.

play
Summary
pdf
MP3 Audio
0
No votes yet
George L. Bakris, MD, FAHA, FASN

CKD in the Light of The SHARP Trial

Faculty: George L. Bakris, MD, FAHA, FASN

Tags:

Individuals with chronic kidney disease (CKD) have raised levels of triglycerides and decreased levels of high-density lipoprotein cholesterol (HDL-C), as well as elevations in low-density lipoprotein cholesterol (LDL-C).

play
Summary
pdf
MP3 Audio
0
No votes yet
Daniel J. Rader, MD, FNLA

HDL Functionality: How Do We Measure It and Is It Relevant to Everyday Clinical Practice?

Faculty: Daniel J. Rader, MD, FNLA

Tags:

It is not universally acknowledged that the relationship between high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) risk is truly causal, and that targeting HDL-C levels automatically reduces risk.

play
Summary
pdf
MP3 Audio
0
No votes yet



by Dr. Radut.